What is congenital rubella syndrome?

Congenital rubella syndrome (CRS) occurs when a pregnant woman without rubella immunity is infected by the rubella virus during the first trimester. The virus infects the placenta and fetus, causing widespread fetal damage during organogenesis. CRS causes: sensorineural deafness (the most common manifestation); congenital heart defects (PDA, pulmonary artery stenosis); cataracts and other eye abnormalities; intellectual disability; microcephaly; and multiple other abnormalities. Approximately 100,000 babies are born with CRS each year — every case is preventable with MMR vaccination.

How dangerous is rubella in pregnancy?

Rubella is dangerous to the fetus at a very specific time window. Maternal rubella infection: first 8-10 weeks of pregnancy — approximately 85-90% of exposed fetuses develop CRS (often multiple defects, most severe); weeks 11-16 — approximately 10-20% develop defects (particularly deafness and cataracts); after 16 weeks — severe CRS becomes uncommon (though late-onset manifestations can occur). Rubella in pregnancy also causes: miscarriage (approximately 20% first trimester); intrauterine fetal death; and growth restriction.

Why is postnatal rubella mild but fetal rubella so devastating?

In children and adults, rubella causes a mild self-limiting illness — fever, rash (characteristically starting on the face and moving downward), lymphadenopathy (particularly posterior cervical and occipital). Polyarthritis is common in adult women. The illness typically resolves within 3-5 days. The harm to the fetus is not from direct immune damage (as in the adult) but from the viral replication in rapidly developing fetal tissues — disrupting organogenesis at critical developmental windows.

How does the MMR vaccine prevent CRS?

The MMR (measles-mumps-rubella) vaccine contains live attenuated rubella virus — inducing durable immunity (>95% protection with two doses) that prevents maternal rubella infection and therefore prevents CRS entirely. Two-dose childhood vaccination — typically at 12 months and 4-5 years — is the standard WHO recommendation. Vaccination of susceptible adolescent and adult women provides additional protection. Countries that have achieved high two-dose MMR coverage have eliminated CRS.

Which countries have eliminated rubella?

The WHO Region of the Americas achieved rubella elimination in 2015 — the first region. The WHO European Region achieved elimination in 2017 (though with recent resurgence in some countries from vaccination gaps). The Western Pacific Region achieved elimination in 2012. The Eastern Mediterranean, African and South-East Asian regions have not yet achieved elimination — bearing the majority of the remaining global CRS burden. Global rubella eradication (following global elimination) remains a future aspiration contingent on sustained vaccination.

Is the MMR vaccine safe in pregnancy?

No — the MMR vaccine is a live attenuated vaccine and is contraindicated in pregnancy (theoretical risk of fetal rubella infection from the vaccine strain, though no confirmed cases of vaccine-related CRS exist). Women should not become pregnant within 28 days of receiving MMR. However, inadvertent MMR vaccination in early pregnancy does NOT warrant therapeutic abortion — there is no documented risk of CRS from the vaccine strain. MMR vaccination should be offered to seronegative women after delivery (before leaving the maternity unit) with counselling about contraception for 28 days.

How does GMJ News cover rubella and CRS?

GMJ News covers WHO rubella elimination data and 2030 targets, CRS burden in LMICs, MMR vaccination programme performance, rubella serosurveillance, and postpartum MMR vaccination. Rubella elimination is a WHO regional target for the European region — directly relevant to PHIG's immunisation programme and Georgia's vaccination coverage monitoring.

Home › Topics › Rubella and Congenital Rubella Syndrome

Rubella and Congenital Rubella Syndrome

GMJ News knowledge hub · last reviewed September 2026 · Georgian Medical Journal

Summary Statistics Glossary GMJ news FAQ Documents Organizations Research

Rubella — a mild febrile rash illness in children and adults — causes catastrophic fetal damage when a pregnant woman is infected during the first trimester: congenital rubella syndrome (CRS) causes deafness, blindness (cataracts/glaucoma), congenital heart defects and intellectual disability in approximately 100,000 babies per year globally, entirely preventable by the MMR (measles-mumps-rubella) vaccine (WHO). WHO targets elimination of rubella and CRS in all regions by 2030 — a goal within reach with sustained vaccination. Despite the availability of an effective, inexpensive vaccine, rubella elimination has stalled in parts of Africa, Southeast Asia and the Eastern Mediterranean, where CRS continues to devastate families.

Key messages

100,000 CRS babies/year — entirely preventable

Congenital rubella syndrome affects approximately 100,000 babies per year globally — causing deafness, blindness, congenital heart defects and intellectual disability from rubella infection during the first trimester of pregnancy. Every single case is vaccine-preventable.

MMR vaccine is the solution

The MMR (measles-mumps-rubella) vaccine — inexpensive, safe, effective — provides >95% protection against rubella. Universal childhood vaccination and vaccination of women of childbearing age eliminates rubella and CRS. Many countries have achieved rubella elimination.

First trimester most dangerous

Rubella infection in the first 8-10 weeks of pregnancy causes severe CRS in approximately 85-90% of exposed fetuses; 11-16 weeks, approximately 10-20% are affected; after 16 weeks, fetal defects are rare. Maternal rubella causes intrauterine growth restriction, miscarriage and stillbirth.

WHO 2030 elimination target

WHO targets elimination of rubella and CRS in all regions by 2030. Most WHO regions have achieved or are close to elimination; Sub-Saharan Africa and parts of Southeast Asia have stalled rubella vaccination progress.

Rubella itself is mild — the danger is in pregnancy

Postnatal rubella is typically a mild, self-limiting illness (rash, lymphadenopathy, low-grade fever) — with joint pain (polyarthritis) more common in adults. The danger of rubella lies entirely in its devastating impact on the fetus.

Congenital rubella babies are infectious

Babies born with CRS shed rubella virus for months — posing a risk to unvaccinated pregnant contacts. Universal neonatal screening and precautions are important.

Key statistics

~100K

CRS cases/year globally (LMICs)

WHO

85-90%

risk of CRS with rubella in first 8-10 weeks of pregnancy

WHO

>95%

protection provided by MMR vaccine

WHO

2030

WHO rubella and CRS elimination target (all regions)

WHO

$1-2

approximate cost of rubella vaccine per dose

WHO/GAVI

Eliminated

rubella status in WHO Americas, European and Western Pacific regions

WHO

CRS cases by WHO region — estimated annual burden

Source: WHO. South-East Asia and Sub-Saharan Africa bear the majority of remaining CRS burden.

Glossary of key terms

Rubella virus
WHOA positive-sense RNA virus (family Matonaviridae, previously Togaviridae) — transmitted by respiratory droplets. Humans are the only reservoir. Postnatal rubella: mild rash illness; polyarthritis in adult women. Congenital rubella: devastating fetal damage during organogenesis.

Classic CRS triad
WHO/ClinicalThe three classic CRS manifestations — sensorineural deafness (most common — bilateral, permanent; from cochlear damage); ocular defects (cataracts, glaucoma, microphthalmia, pigmentary retinopathy); congenital heart defects (patent ductus arteriosus and pulmonary artery stenosis most common).

Extended CRS manifestations
WHOBeyond the classic triad: intellectual disability; microcephaly; autism; thrombocytopenic purpura (characteristic "blueberry muffin" rash from dermal haematopoiesis); hepatosplenomegaly; neonatal meningitis; bone radiolucency ("celery stalk" on X-ray); late manifestations (type 1 diabetes, thyroid disease, progressive rubella panencephalitis — rare).

MMR vaccine
WHO EMLCombined live attenuated measles-mumps-rubella vaccine — among the safest and most effective vaccines ever developed. A two-dose schedule provides >97% protection against all three diseases. WHO recommends two doses in childhood. On WHO Essential Medicines List. Single and combined preparations available.

Rubella elimination
WHOInterruption of endemic rubella virus transmission in a defined geographic region. WHO defines elimination as incidence <1 per million population over 12 months and absence of indigenous transmission for 12+ months. Americas (2015), Europe (2020), Western Pacific and other regions have achieved or near-achieved elimination. Global eradication is a future goal.

Serosurveillance and catch-up vaccination
WHOTesting women of childbearing age for rubella seropositivity — and vaccinating those who are seronegative before pregnancy — is a key strategy. In countries introducing rubella vaccine after rubella has circulated for years, catch-up vaccination campaigns for adolescent girls and women are needed to close immunity gaps.